Mark Platt






Mark Platt took the helm of gene-editing company Recombinetics in February, on the heels of a $34 million Series A fundraising round. Platt quickly got to work, rounding out the company’s leadership and gearing up for growth. He named a new chief scientific officer, head of research and development, and leader for its lab operations. Platt also helped secure better facilities to help advance Recombinetics’ mission to improve human and animal health through gene editing. And he has big ambitions for Acceligen, the company’s ag-focused subsidiary; to prep for fundraising, he appointed Acceligen’s first CEO, commercialization director, and board of directors.